Table 3.

Autologous HSCT.

Probability of overall survival (OS), relapse free survival (RFS), relapse incidence (RI), and non-relapse mortality (NRM) after HSCT depending on center specific economic factors.

Numbers represent hazard ratios (HR), adjusted for all other risk factors by stratification (see Methods section for details).

	OS	RFS	RI	NRM
Accreditation
JACIE −	1	1	1	1
JACIE +	1·08 [1·00–1·15]	1·04 [0·99–1·11]	1·07 [0·99–1·17]	0·93 [0·80–1·07]
Center patient volume
Per 10 patients	0·91 [0·87–0·96]	0·93 [0·89–0·97]	0·92 [0·87–0·98]	0·96 [0·87–1·07]
0–4 patients	1	1	1	1
5–9 patients	0·96	0·96	0·96	0·93
10–14 patients	0·97	0·95	0·95	0·97
15–19 patients	0·94	0·93	0·94	0·90
> 20 patients	0·84	0·87	0·86	0·92
Center program duration
Per 10 years	0·93 [0·87–0·99]	0·92 [0·87–0·98]	0·92 [0·84–0·98]	0·99 [0·88–1·11]
0–4 years	1	1	1	1
5–9 years	0·98	0·93	0·92	0·96
10–14 years	0·97	0·91	0·89	0·99
15–19 years	0·91	0·80	0·88	0·95
EBMT risk score
Per score point	1·17 [1·15–1·19]	1·14 [1·12–1·16]	1·10 [1·08–1·13]	1·30 [1·26–1·34]

Multiplier of the hazard ratio (interaction term in model) for the difference in speed of improvement between accredited and non-accredited centers.

EBMT risk score (score points 0–7 for allogeneic, 0–5 for autologous HSCT: age of patient: < 20 years = 0, 20–40 years = 1, > 40 = 2; disease stage: early = 0, intermediate = 1, advanced = 2; time interval from diagnosis to transplant: < 1 year = 0, > 1 year = 1; allogeneic HSCT only: donor type: HLA id sibling = 0; other donor = 1; donor recipient gender combination: all other = 0, female donor for male recipient = 1).